 UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS Merus, we and our, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and TriclonicsTM, today announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of 24.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately 120 million. In addition, Merus granted the underwriters a 30-day option to purchase up to an additional 727,272 common shares at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering are to be sold by Merus. 